Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
September 09, 2024 07:00 ET
|
Autonomix Medical, Inc.
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction...
Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
August 21, 2024 08:30 ET
|
Autonomix Medical, Inc.
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
August 13, 2024 08:00 ET
|
Autonomix Medical, Inc.
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
August 02, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
July 24, 2024 08:00 ET
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA regulatory...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
July 22, 2024 09:05 ET
|
Autonomix Medical, Inc.
Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement
July 18, 2024 08:30 ET
|
Autonomix Medical, Inc.
Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc. THE WOODLANDS, TX, July 18, 2024 (GLOBE...
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
July 15, 2024 08:00 ET
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
July 11, 2024 09:00 ET
|
Autonomix Medical, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO Corner Here! THE WOODLANDS, TX, July 11,...